At a hearing of the US Senate Judiciary Committee, the Federal Trade Commission called for moves to prevent agreements between brand-name pharmaceutical companies and generic drugmakers to delay entry to the market of copy products, which has been possible under the provisions of the Hatch-Waxman legislation.
Committee chairman Patrick Leahy (Democrat, Vermont) put forward a bill at the hearing which would bar such deals. He said that these agreements between R&D and generics firms were tantamount to "collusion that limits consumer choices and keeps consumer prices artificially high," noting that "Congress never intended for brand-name drug companies to be able to pay off generic companies not to produce generic medicines."
Also testifying was Senator Arlen Specter (Republican, Pennsylvania), who said: "I do think there's a burden on people making these settlements to show why they are not anti-competitive," but added: "is it wise for the Congress to have a sweeping generalization that this is a per se violation?"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze